NASDAQ:ARDX Ardelyx - ARDX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.06 +0.14 (+3.57%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.94▼$4.2350-Day Range$2.75▼$4.1452-Week Range$0.49▼$4.23Volume6.64 million shsAverage Volume7.65 million shsMarket Capitalization$838.36 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ardelyx MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside47.8% Upside$6.00 Price TargetShort InterestBearish5.32% of Shares Sold ShortDividend StrengthN/ASustainability-1.32Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$60,225 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.30) to $0.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector300th out of 989 stocksPharmaceutical Preparations Industry126th out of 480 stocks 3.4 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Ardelyx has a forecasted upside of 47.8% from its current price of $4.06.Amount of Analyst CoverageArdelyx has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.32% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ardelyx has recently increased by 8.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArdelyx has received a 66.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Constipation medication (A06)" products. See details.Environmental SustainabilityThe Environmental Impact score for Ardelyx is -1.32. Previous Next 3.1 News and Social Media Coverage News SentimentArdelyx has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Ardelyx this week, compared to 2 articles on an average week.Search Interest118 people have searched for ARDX on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.MarketBeat Follows28 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,225.00 in company stock.Percentage Held by InsidersOnly 6.00% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions40.44% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.30) to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -8.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -8.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 8.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ardelyx (NASDAQ:ARDX) StockArdelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA.Read More Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDX Stock News HeadlinesMarch 22, 2023 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Shares Down 6.7% March 15, 2023 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Upgraded by StockNews.com to BuyMarch 24, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 14, 2023 | americanbankingnews.comFinancial Analysis: Ardelyx (NASDAQ:ARDX) & Prelude Therapeutics (NASDAQ:PRLD)March 4, 2023 | finance.yahoo.comAnalysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging HigherMarch 3, 2023 | finance.yahoo.comArdelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 3, 2023 | finance.yahoo.comArdelyx (ARDX) Surpasses Q4 Earnings and Revenue EstimatesFebruary 27, 2023 | finance.yahoo.comArdelyx to Participate at the Cowen 43rd Annual Health Care ConferenceMarch 24, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 23, 2023 | finance.yahoo.comArdelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023February 20, 2023 | finance.yahoo.comAre Medical Stocks Lagging Ardelyx (ARDX) This Year?February 16, 2023 | finance.yahoo.comArdelyx (ARDX) Stock Sinks As Market Gains: What You Should KnowFebruary 15, 2023 | finance.yahoo.comArdelyx Inc. (ARDX) to Report Q4 Earnings: What's in Store?February 9, 2023 | finance.yahoo.comArdelyx (ARDX) Gains As Market Dips: What You Should KnowFebruary 6, 2023 | finance.yahoo.comArdelyx, Inc. (NASDAQ:ARDX) Is Expected To Breakeven In The Near FutureFebruary 3, 2023 | finance.yahoo.comArdelyx (ARDX) Outpaces Stock Market Gains: What You Should KnowDecember 29, 2022 | finance.yahoo.comFDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)December 29, 2022 | finance.yahoo.comArdelyx stock rises as FDA grants appeal for new drug application for XphozahDecember 27, 2022 | finance.yahoo.comThe 29% return this week takes Ardelyx's (NASDAQ:ARDX) shareholders one-year gains to 134%December 19, 2022 | finance.yahoo.comFDA Needs More Time For Ardelyx's Appeal To Rejection Of Kidney Disease CandidateDecember 6, 2022 | finance.yahoo.comBullish insiders bet US$1.0m on Ardelyx, Inc. (NASDAQ:ARDX)November 22, 2022 | finance.yahoo.comArdelyx to Present at the 34th Annual Piper Sandler Healthcare ConferenceNovember 18, 2022 | finance.yahoo.comArdelyx (ARDX) Up 41% After FDA Committee Endorses CKD DrugNovember 18, 2022 | finance.yahoo.comAnalyst Sees This Kidney Disease Company's Stock Could Rise Sixfold, But Lists Two IssuesNovember 17, 2022 | finance.yahoo.comDespite Concerns, FDA Advisory Committee Votes In Favor Of Ardelyx's Kidney Disease CandidateNovember 17, 2022 | investorplace.comWhy Is Ardelyx (ARDX) Stock Up 38% Today?November 16, 2022 | finance.yahoo.comArdelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on DialysisSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDX Company Calendar Last Earnings11/12/2021Today3/24/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARDX CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees86Year Founded2007Price Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+47.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,210,000.00 Net Margins-128.85% Pretax Margin-128.84% Return on Equity-95.19% Return on Assets-45.12% Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.29 Sales & Book Value Annual Sales$52.16 million Price / Sales16.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book8.12Miscellaneous Outstanding Shares206,493,000Free Float194,103,000Market Cap$838.36 million OptionableOptionable Beta1.10 Social Links Key ExecutivesMike RaabPresident, Chief Executive Officer & DirectorJustin A. RenzChief Financial, Operations Officer & TreasurerLaura A. WilliamsChief Medical OfficerElizabeth GrammerSecretary, Chief Legal & Administrative OfficerDavid P. RosenbaumChief Development OfficerKey CompetitorsCollegium PharmaceuticalNASDAQ:COLLKura OncologyNASDAQ:KURAEnanta PharmaceuticalsNASDAQ:ENTAImmunoGenNASDAQ:IMGNCrinetics PharmaceuticalsNASDAQ:CRNXView All CompetitorsInsiders & InstitutionsNatixisBought 77,500 shares on 2/24/2023Ownership: 0.039%Michael RaabSold 13,449 sharesTotal: $40,347.00 ($3.00/share)Justin A RenzSold 3,439 sharesTotal: $10,317.00 ($3.00/share)Laura A WilliamsSold 3,187 sharesTotal: $9,561.00 ($3.00/share)Morgan StanleyBought 714,798 shares on 2/15/2023Ownership: 0.708%View All Insider TransactionsView All Institutional Transactions ARDX Stock - Frequently Asked Questions Should I buy or sell Ardelyx stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares. View ARDX analyst ratings or view top-rated stocks. What is Ardelyx's stock price forecast for 2023? 4 brokers have issued 12-month price targets for Ardelyx's stock. Their ARDX share price forecasts range from $3.00 to $8.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 47.8% from the stock's current price. View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts. How have ARDX shares performed in 2023? Ardelyx's stock was trading at $2.85 at the beginning of 2023. Since then, ARDX shares have increased by 42.5% and is now trading at $4.06. View the best growth stocks for 2023 here. Are investors shorting Ardelyx? Ardelyx saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 10,990,000 shares, an increase of 8.7% from the February 13th total of 10,110,000 shares. Based on an average trading volume of 7,590,000 shares, the short-interest ratio is currently 1.4 days. View Ardelyx's Short Interest. When is Ardelyx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our ARDX earnings forecast. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.07. The biopharmaceutical company had revenue of $1.17 million for the quarter, compared to analyst estimates of $0.85 million. Ardelyx had a negative trailing twelve-month return on equity of 95.19% and a negative net margin of 128.85%. What ETFs hold Ardelyx's stock? ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD). What is Ardelyx's stock symbol? Ardelyx trades on the NASDAQ under the ticker symbol "ARDX." Who are Ardelyx's major shareholders? Ardelyx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Orchard Capital Management LLC (1.46%), Two Sigma Investments LP (1.18%), Price T Rowe Associates Inc. MD (1.16%), Lion Point Capital LP (0.95%), Geode Capital Management LLC (0.87%) and Pekin Hardy Strauss Inc. (0.84%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ardelyx's stock price today? One share of ARDX stock can currently be purchased for approximately $4.06. How much money does Ardelyx make? Ardelyx (NASDAQ:ARDX) has a market capitalization of $838.36 million and generates $52.16 million in revenue each year. The biopharmaceutical company earns $-67,210,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. How can I contact Ardelyx? Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493. This page (NASDAQ:ARDX) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.